West Nile virus (WNV) is a re-emerging mosquito-borne and zoonotic viral infection which is largely underestimated in Nigeria. This study sought to determine the pooled prevalence pattern and risk factors of WNV infection among humans and animals in Nigeria. Methods: A systematic review of eligible articles was conducted from "PubMed", "Scopus", "Google Scholar" and "Web of Science", from 1 st January 1950 to 30 th August 2020. Peer-reviewed articles describing WNV infection of humans and animals in cross-sectional studies were systematically reviewed and analyzed. Cochrane Q was used to determine the heterogeneity of studies reports. Results: About 61.5% human studies had low risk of bias. Howewer, all had high heterogeneity. Southwestern Nigeria had the highest pooled prevalence of anti-WNV IgM, 7.8% in humans. The pooled WNV IgM and IgG seroprevalence were 7.1% (95% CI: 5.9-8.3) and 76.5% (95% CI: 74.0-78.8), respectively. The WNV RNA prevalence was 1.9% (95% CI: 1.4-2.9), while 14.3% (95% CI: 12.9-15.8) had WNV neutralizing antibodies. In animals, the pooled WNV IgM and IgG seroprevalence were 90.3% (95% CI: 84.3-94.6) and 3.5% (95% CI: 1.9-5.8), respectively while 20.0% (95% CI: 12.9-21.4) had WNV neutralizing antibodies. Age (OR=3.73, 95% CI: 1.87-7.45; p=0.0002) and level of education [no formal education (OR=4.31, CI: 1.08-17.2; E p u b a h e a d o f p r i n t 2 p=0.0386), primary (OR=7.29, 95% CI: 1.80-29.6; p=0.0054)], were significant risk factors of WNV IgM seropositivity in humans. Conclusion: Findings from this study highlighted the endemicity of WNV infection in animals and humans in Nigeria and underscored the need for "One health" prevention and control approach against WNV infection.
As the coronavirus disease 2019 (COVID-19) pandemic continues to rise and second waves are reported in some countries, serological test kits and strips are being considered to scale up an adequate laboratory response. This study provides an update on the kinetics of humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and performance characteristics of serological protocols (lateral flow assay [LFA], chemiluminescence immunoassay [CLIA] and ELISA) used for evaluations of recent and past SARS-CoV-2 infection. A thorough and comprehensive review of suitable and eligible full-text articles was performed on PubMed, Scopus, Web of Science, Wordometer and medRxiv from 10 January to 16 July 2020. These articles were searched using the Medical Subject Headings terms ‘COVID-19’, ‘Serological assay’, ‘Laboratory Diagnosis’, ‘Performance characteristics’, ‘POCT’, ‘LFA’, ‘CLIA’, ‘ELISA’ and ‘SARS-CoV-2’. Data from original research articles on SARS-CoV-2 antibody detection ≥second day postinfection were included in this study. In total, there were 7938 published articles on humoral immune response and laboratory diagnosis of COVID-19. Of these, 74 were included in this study. The detection, peak and decline period of blood anti-SARS-CoV-2 IgM, IgG and total antibodies for point-of-care testing (POCT), ELISA and CLIA vary widely. The most promising of these assays for POCT detected anti-SARS-CoV-2 at day 3 postinfection and peaked on the 15th day; ELISA products detected anti-SARS-CoV-2 IgM and IgG at days 2 and 6 then peaked on the eighth day; and the most promising CLIA product detected anti-SARS-CoV-2 at day 1 and peaked on the 30th day. The most promising LFA, ELISA and CLIA that had the best performance characteristics were those targeting total SARS-CoV-2 antibodies followed by those targeting anti-SARS-CoV-2 IgG then IgM. Essentially, the CLIA-based SARS-CoV-2 tests had the best performance characteristics, followed by ELISA then POCT. Given the varied performance characteristics of all the serological assays, there is a need to continuously improve their detection thresholds, as well as to monitor and re-evaluate their performances to assure their significance and applicability for COVID-19 clinical and epidemiological purposes.
T helper 17 (Th17) are a CD4+ T subpopulation cells which are involved in the host protection against microbes such as extracellular and intracellular bacteria, parasites, fungi, and viruses. Monogenic defects including those mutations in some genes such as the signal transducer and activator of transcription (STAT)1 and 3, dedicator of cytokinesis 8 (DOCK8), autoimmune regulator (AIRE), and interleukin 17 receptor A (IL-17RA) can lead to impairment in Th17 cell development and function along with the concomitant increased risk for chronic mucocutaneous candidiasis (CMC). The immunologic abnormalities in these patients include low frequency of Th17 cells; defective cutaneous or in vitro T cell response to Candida species, and/or autoantibodies against relevant cytokines. This review outlines the biological characteristics and functionality of Th17 cells, as well as the clinical features of individuals with genetic defects associated with Th17 deficiency.
Postoperative analgesic effects of tramadol and diclofenac in goats presented for diaphyseal femoral fracture management were compared. Eight adult goats aged 10 to 24 months (16±5.2 months) were used. The first group of 4 goats received 3 mg/kg of tramadol intramuscularly (IM), and 2.5 mg/kg of diclofenac sodium was administered to the second group of 4 goats before induction of anesthesia IM. Mechanical pain scores, clinico-physiological and red and white blood cell counts were evaluated over a period of twelve hours post drug administration. The study groups were not revealed to the postoperative pain assessors until the end of the study. There was no significant difference in the rectal temperature values and the analgesiometer readings between the tramadol and diclofenac groups (p<0.05). The variations in the pulse rate, respiratory rate, red and white blood cell counts between the groups fluctuated within the normal physiological limits.It was therefore concluded that preoperative intramuscular administration of tramadol at 3 mg/kg provided similar effective postoperative analgesia with diclofenac at 2.5 mg/kg IM following femoral diaphyseal fracture management in goats.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.